Literature DB >> 15618961

CEBPalpha mutations in childhood acute myeloid leukemia.

D-C Liang1, L-Y Shih, C-F Huang, I-J Hung, C-P Yang, H-C Liu, T-H Jaing, L-Y Wang, W-H Chang.   

Abstract

CEBPalpha: mutations have been described in adult acute myeloid leukemia (AML) and conferred a favorable prognosis. However, CEBPalpha mutation has not been reported in children. We investigated 117 children with de novo AML using DNA PCR assay followed by sequencing for each PCR product. CEBPalpha mutations were detected in seven patients, four had FAB M2, two M1 and one M4. CEBPalpha mutations only occurred in patients with intermediate cytogenetics and not in 56 children with AML1-ETO, CBFbeta-MYH11, PML-RARalpha or MLL rearrangements. Five patients had mutations occurred in both N-terminal part and basic-leucine zipper (bZIP) domain, one had an N-terminal frameshift mutation and the remaining one had an inframe insertion in the bZIP domain. Cloning analysis on five samples carrying more than one mutations demonstrated one homozygous combined mutations and four heterozygous biallelic mutations. Four of seven CEBPalpha mutation(+) patients had cooperating mutations with FLT3-ITD or N-ras mutations compared to 27 in 109 CEBPalpha mutation(-) patients. Our results showed that CEBPalpha mutations occurred in 6% of childhood AML and most exhibited combined mutations in both N-terminal part and bZIP domain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15618961     DOI: 10.1038/sj.leu.2403608

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Effect of genetic variation of CEBPA gene on body measurement and carcass traits of Qinchuan cattle.

Authors:  Hua He; Xiaolin Liu; Yulan Gu; Yu Liu; Jing Yang
Journal:  Mol Biol Rep       Date:  2010-12-24       Impact factor: 2.316

2.  DNMT3A mutations are rare in childhood acute myeloid leukemia.

Authors:  Felicitas Thol; Michael Heuser; Frederik Damm; Jan-Henning Klusmann; Katarina Reinhardt; Dirk Reinhardt
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

Review 3.  Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.

Authors:  Kelly Faulk; Lia Gore; Todd Cooper
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

4.  High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells.

Authors:  Veronika Kanderova; Daniela Kuzilkova; Jan Stuchly; Martina Vaskova; Tomas Brdicka; Karel Fiser; Ondrej Hrusak; Fridtjof Lund-Johansen; Tomas Kalina
Journal:  Mol Cell Proteomics       Date:  2016-01-19       Impact factor: 5.911

5.  Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.

Authors:  Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Martin Zimmermann; Justine K Peeters; Peter J M Valk; Brian V Balgobind; Edwin Sonneveld; Gertjan J L Kaspers; Eveline S J M de Bont; Jan Trka; Andre Baruchel; Ursula Creutzig; Rob Pieters; Dirk Reinhardt; C Michel Zwaan
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

6.  Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.

Authors:  Yasuhiro Mizushima; Tomohiko Taki; Akira Shimada; Yoshihiro Yui; Yoshimi Hiraumi; Hiroshi Matsubara; Motonobu Watanabe; Ken-ichiro Watanabe; Yuri Kamitsuji; Yasuhide Hayashi; Ichiro Tsukimoto; Ryoji Kobayashi; Keizo Horibe; Akio Tawa; Tatsutoshi Nakahata; Souichi Adachi
Journal:  Int J Hematol       Date:  2010-05-22       Impact factor: 2.490

7.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.

Authors:  Phoenix A Ho; Todd A Alonzo; Robert B Gerbing; Jessica Pollard; Derek L Stirewalt; Craig Hurwitz; Nyla A Heerema; Betsy Hirsch; Susana C Raimondi; Beverly Lange; Janet L Franklin; Jerald P Radich; Soheil Meshinchi
Journal:  Blood       Date:  2009-03-20       Impact factor: 22.113

Review 8.  Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions.

Authors:  Long Su; Yuan-Yuan Shi; Zeng-Yan Liu; Su-Jun Gao
Journal:  Front Oncol       Date:  2022-02-01       Impact factor: 6.244

9.  C/EBPalpha or C/EBPalpha oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-kappaB p50 bound to the bcl-2 and FLIP gene promoters.

Authors:  I Paz-Priel; A K Ghosal; J Kowalski; A D Friedman
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

10.  Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

Authors:  H Matsuo; M Kajihara; D Tomizawa; T Watanabe; A M Saito; J Fujimoto; K Horibe; K Kodama; M Tokumasu; H Itoh; H Nakayama; A Kinoshita; T Taga; A Tawa; T Taki; S Tanaka; S Adachi
Journal:  Blood Cancer J       Date:  2014-07-11       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.